NasdaqCM - Nasdaq Real Time Price USD

Viridian Therapeutics, Inc. (VRDN)

12.39

-0.39

(-3.05%)

At close: May 9 at 4:00:02 PM EDT

12.36

-0.03

(-0.24%)

After hours: May 9 at 4:24:09 PM EDT

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

WALTHAM, Mass., May 07, 2025--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to veligrotug ("veli"), the company’s lead anti-insulin-like growth factor-1 receptor (IGF-1R) drug candidate for the treatment of TED.

Business Wire 2 days ago

VRDN
-3.05%
Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations

Viridian Therapeutics ( NASDAQ:VRDN ) First Quarter 2025 Results Key Financial Results Net loss: US$86.9m (loss widened...

Simply Wall St. 3 days ago

VRDN
-3.05%
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

WALTHAM, Mass., May 06, 2025--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2025.

Business Wire 4 days ago

VRDN
-3.05%
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 02, 2025--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company’s common stock to 13 new employees (the "

Business Wire 8 days ago

VRDN
-3.05%
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

WALTHAM, Mass., April 07, 2025--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors.

Business Wire last month

VRDN
-3.05%
Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Viridian Therapeutics ( NASDAQ:VRDN ) Full Year 2024 Results Key Financial Results Net loss: US$269.9m (loss widened by...

Simply Wall St. 2 months ago

VRDN
-3.05%
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

WALTHAM, Mass., February 27, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024.

Business Wire 2 months ago

VRDN
-3.05%
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s key priorities and catalysts for 2025.

Business Wire 3 months ago

VRDN
-3.05%
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?

Key Insights The projected fair value for Viridian Therapeutics is US$14.53 based on 2 Stage Free Cash Flow to Equity...

Simply Wall St. 4 months ago

VRDN
-3.05%
Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in patients with chronic thyroid eye disease. TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eyes. THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after five infusions of veligrotug, showing statistical

TipRanks 4 months ago

VRDN
-3.05%
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen

Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell.

Investor's Business Daily 4 months ago

VRDN
-3.05%

AMGN
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

WALTHAM, Mass., December 16, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). TED is an autoimmune condition characterize

Business Wire 4 months ago

VRDN
-3.05%
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

WALTHAM, Mass., December 13, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET.

Business Wire 4 months ago

VRDN
-3.05%
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Viridian Therapeutics ( NASDAQ:VRDN ) Third Quarter 2024 Results Key Financial Results Net loss: US$76.7m (loss widened...

Simply Wall St. 5 months ago

VRDN
-3.05%
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

WALTHAM, Mass., November 12, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ending September 30, 2024.

Business Wire 5 months ago

VRDN
-3.05%
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St. 6 months ago

VRDN
-3.05%
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

WALTHAM, Mass., September 12, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferred stock. Viridian is selling a total of 10,666,600 shares of common stock at a public offering pric

Business Wire 7 months ago

VRDN
-3.05%
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

WALTHAM, Mass., September 10, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian in

Business Wire 7 months ago

VRDN
-3.05%
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

WALTHAM, Mass., September 10, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmune condition cha

Business Wire 7 months ago

VRDN
-3.05%
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

WALTHAM, Mass., September 09, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, will host a conference call and webcast to report topline data for the THRIVE phase 3 clinical trial, evaluating VRDN-001 in patients with active TED, on Tuesday, September 10, 2024 at 8:00am ET.

Business Wire 7 months ago

VRDN
-3.05%

Performance Overview

Return	VRDN	S&P 500 (^GSPC)
YTD	-35.37%	-3.77%
1-Year	-10.93%	+8.55%
3-Year	+29.74%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?

Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints

Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Performance Overview